Belite Bio, Inc (NasdaqGS: BLTE)
Health Care · Pharmaceuticals · US
$169.96
+8.99% today · +51.2% 1Y
Belite Bio, Inc (NasdaqGS: BLTE) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $6.84B and employs 41 people.
Over the last twelve months the share price has gained 51.2%, trading between 105.88 and 200.00.
Tweenvest scores Belite Bio, Inc across four factors: quality 41/100, value 76/100. Its strongest factor is value.
BLTE price history
Key figures
- Market cap
- $6.84B
- Revenue (TTM)
- —
- P/E
- -61.69
- EPS
- -2.83
- Dividend yield
- —
- Beta (5Y)
- -1.19
- 52-week high
- $200.00
- 52-week low
- $105.88
- Avg volume (3M)
- —
- Shares outstanding
- 40.27M
- Employees
- 41
- Next earnings
- —
About Belite Bio, Inc
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
- ISIN
- US07782B1044
- Founded
- 2016
- Listed since
- Apr 29, 2022
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| ABIVAX Société AnonymeENXTPA: ABVX | $7.33B | €76.65 | +1.52% |
| Gedeon Richter PLCBUSE: RICHTER | $7.32B | Ft13,500.00 | -0.74% |
| CSPC Innovation Pharmaceutical Co., Ltd.SZSE: 300765 | $7.17B | CN¥34.36 | -2.86% |
| Axsome Therapeutics, Inc.NasdaqGM: AXSM | $7.05B | $134.00 | -1.43% |
| Alkem Laboratories LimitedNSEI: ALKEM | $6.68B | Rs5,222.50 | +0.92% |
| China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.SZSE: 000999 | $6.59B | CN¥26.40 | -0.04% |
| Apotex Health Corp.TSX: APTX | $6.45B | CA$40.28 | +2.13% |
| Ligand Pharmaceuticals IncorporatedNasdaqGM: LGND | $6.33B | $316.27 | -0.18% |